Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...
Arcturus Therapeutics (ARCT) announced the appointment of Moncef Slaoui as chair designate. Slaoui has been serving on the company’s board of ...
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $428 million specializing in mRNA therapeutics and vaccines, stands at a ...
Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public ...
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...
Hosted on MSN6d
BTIG Initiates Coverage of Arcturus Therapeutics Holdings (ARCT) with Buy RecommendationFintel reports that on January 28, 2025, BTIG initiated coverage of Arcturus Therapeutics Holdings (NasdaqGM:ARCT) with a Buy ...
In the assessment of 12-month price targets, analysts unveil insights for Arcturus Therapeutics, presenting an average target ...
In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report), with a ...
BTIG Research began coverage on shares of Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) in a research report issued on Tuesday, MarketBeat reports. The brokerage set a “buy” rating and a ...
This capital helps fund our Energy-as-a-Service offering, allowing us to deploy Arcturus at industrial <a target=_blank href= ...
Equities research analysts at Leerink Partnrs upped their FY2024 EPS estimates for shares of Arcturus Therapeutics in a note ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback